Clinical Trial Update: Sifrol (Pramipexole) Onset of Action and Impact: a 12-weeks Observational Study in Patients With Primary Restless Legs Syndrome

View source ↗

Summary

This completed 12-week observational trial evaluated the onset of action and overall impact of pramipexole (Sifrol) in patients with primary Restless Legs Syndr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Restless Legs Syndrome

Drugs mentioned

• Sifrol (ropinirole)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Restless Legs Syndrome | Status: COMPLETED | Results posted: 2010-01-08